We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+2.89%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
+$29.2M
Cap. Flow
+$147M
Cap. Flow %
5.13%
Top 10 Hldgs %
48.59%
Holding
107
New
12
Increased
2
Reduced
2
Closed
19

Top Buys

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$121M
2
TNGX icon
Tango Therapeutics
TNGX
+$82.4M
3
BPMC
Blueprint Medicines
BPMC
+$39.6M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$37.4M
5
NUVL
Nuvalent
NUVL
+$35.1M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$63.2M
2
AMRN
Amarin Corp
AMRN
+$26.3M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$24M
4
AGEN
Agenus
AGEN
+$22M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$20.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.15%
2 Financials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$354M 12.36%
2,000,000
– –
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$277M 9.69%
764,188
– –
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
$132M 4.6%
2,075,905
– –
ITOS
4
DELISTED
iTeos Therapeutics
ITOS
$117M 4.1%
4,345,016
– –
TYRA icon
5
Tyra Biosciences
TYRA
$1.9B
$111M 3.88%
+6,323,359
New +$121M
RVMD icon
6
Revolution Medicines
RVMD
$39.9B
$95.9M 3.35%
3,484,264
– –
TNGX icon
7
Tango Therapeutics
TNGX
$4.43B
$88.8M 3.1%
+6,871,642
New +$82.4M
CYTK icon
8
Cytokinetics
CYTK
$10.5B
$75.1M 2.62%
2,100,000
– –
RCUS icon
9
Arcus Biosciences
RCUS
$3.55B
$72.7M 2.54%
2,084,883
– –
PMVP icon
10
PMV Pharmaceuticals
PMVP
$59.2M
$67.6M 2.36%
2,268,236
– –
IDYA icon
11
IDEAYA Biosciences
IDYA
$3.42B
$56.1M 1.96%
2,202,812
– –
ARGX icon
12
argenx
ARGX
$53.4B
$51.6M 1.8%
170,926
– –
CNTB
13
Connect Biopharma Holdings
CNTB
$127M
$50.4M 1.76%
2,081,323
– –
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$48.5M 1.69%
1,094,000
– –
RCKT icon
15
Rocket Pharmaceuticals
RCKT
$340M
$43.8M 1.53%
1,466,051
– –
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.69B
$43.7M 1.53%
2,287,782
– –
BPMC
17
DELISTED
Blueprint Medicines
BPMC
$43.7M 1.53%
+425,000
New +$39.6M
NUVB icon
18
Nuvation Bio
NUVB
$2.2B
$43.1M 1.51%
4,341,009
– –
KNTE
19
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$42.5M 1.49%
1,847,559
+781,620
+73% +$17M
MRUS
20
DELISTED
Merus
MRUS
$41.8M 1.46%
1,900,000
– –
RLAY icon
21
Relay Therapeutics
RLAY
$4.1B
$40.8M 1.42%
1,294,132
– –
DBVT
22
DBV Technologies
DBVT
$799M
$36.9M 1.29%
753,460
– –
NRIX icon
23
Nurix Therapeutics
NRIX
$2.41B
$36.7M 1.28%
1,224,892
– –
FULC icon
24
Fulcrum Therapeutics
FULC
$239M
$35.3M 1.23%
+1,250,000
New +$23.7M
ANAB icon
25
AnaptysBio
ANAB
$1.58B
$35.3M 1.23%
1,300,000
– –
1
2 3 4 5

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Boxer Capital held 107 positions worth $2.86B, up 1% from $2.83B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Boxer Capital deployed $147M of net new capital in Q3 2021, opening 12 new positions and adding to 2 existing holdings. Its largest new stake was Tyra Biosciences: 6,323,359 shares worth $111M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Solid Biosciences, an estimated $1.42M trimmed.

  • Boxer Capital's largest Q3 2021 buy was Tyra Biosciences: 6,323,359 shares worth $111M.
  • Boxer Capital added most to Kinnate Biopharma Inc. Common Stock in Q3 2021, an estimated $17M increase.
  • Boxer Capital's biggest Q3 2021 reduction was Solid Biosciences, cutting an estimated $1.42M.
  • Boxer Capital fully exited Seagen Inc. Common Stock in Q3 2021, selling an estimated $63.2M.
  • Boxer Capital's ten largest holdings make up 49% of its $2.86B portfolio in Q3 2021.
  • Boxer Capital opened 12 new positions and closed 19 in Q3 2021.
  • Boxer Capital's portfolio value rose 1% quarter-over-quarter to $2.86B.

Based on Boxer Capital's 13F filing for Q3 2021, filed 15 Nov 2021.